Stock Analysis

3 Growth Companies With High Insider Ownership And 27% Revenue Growth

SHSE:688213
Source: Shutterstock

In a week marked by record highs across major indices like the Dow Jones Industrial Average and S&P 500, global markets have shown resilience despite geopolitical tensions and tariff concerns. As investors navigate these buoyant yet complex conditions, high insider ownership in growth companies can be an indicator of strong alignment between management and shareholders, potentially leading to sustained revenue growth.

Top 10 Growth Companies With High Insider Ownership

NameInsider OwnershipEarnings Growth
Seojin SystemLtd (KOSDAQ:A178320)30.9%39.9%
People & Technology (KOSDAQ:A137400)16.4%37.3%
Kirloskar Pneumatic (BSE:505283)30.3%26.3%
Archean Chemical Industries (NSEI:ACI)22.9%41.3%
SKS Technologies Group (ASX:SKS)32.4%24.8%
Medley (TSE:4480)34%31.7%
Fine M-TecLTD (KOSDAQ:A441270)17.2%131.1%
Fulin Precision (SZSE:300432)13.6%66.7%
HANA Micron (KOSDAQ:A067310)18.4%110.9%
Findi (ASX:FND)34.8%112.9%

Click here to see the full list of 1512 stocks from our Fast Growing Companies With High Insider Ownership screener.

Here's a peek at a few of the choices from the screener.

Smartsens Technology (Shanghai) (SHSE:688213)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Smartsens Technology (Shanghai) Co., Ltd. operates in the semiconductor industry, focusing on designing and manufacturing CMOS image sensors, with a market cap of CN¥28.42 billion.

Operations: The company's revenue primarily comes from its Semiconductor Integrated Circuit Chips segment, totaling CN¥5.29 billion.

Insider Ownership: 24.4%

Revenue Growth Forecast: 27.1% p.a.

Smartsens Technology (Shanghai) demonstrates significant growth potential with forecasted revenue and earnings growth rates of 27.1% and 48.4% per year, respectively, outpacing the broader Chinese market. Recently profitable, the company reported CNY 4.21 billion in sales for the first nine months of 2024, up from CNY 1.77 billion a year ago. Despite high share price volatility and low future return on equity projections, its recent share buyback indicates confidence in long-term value creation.

SHSE:688213 Earnings and Revenue Growth as at Dec 2024
SHSE:688213 Earnings and Revenue Growth as at Dec 2024

Lepu Medical Technology (Beijing) (SZSE:300003)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Lepu Medical Technology (Beijing) Co., Ltd. operates in the healthcare sector, focusing on the development and manufacturing of medical devices and pharmaceuticals, with a market cap of approximately CN¥22.10 billion.

Operations: Lepu Medical Technology (Beijing) Co., Ltd. generates its revenue through the development and manufacturing of medical devices and pharmaceuticals.

Insider Ownership: 13.7%

Revenue Growth Forecast: 15.9% p.a.

Lepu Medical Technology (Beijing) shows potential for growth, with earnings expected to rise significantly at 36.8% annually, outpacing the Chinese market. Despite a decline in profit margins from 19.2% to 10.9%, the company maintains a favorable valuation with a price-to-earnings ratio of 32x below the market average. Recent buybacks totaling CNY 252.65 million suggest confidence in value creation, though revenue forecasts indicate slower growth compared to peers at 15.9% per year.

SZSE:300003 Earnings and Revenue Growth as at Dec 2024
SZSE:300003 Earnings and Revenue Growth as at Dec 2024

Visional (TSE:4194)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Visional, Inc., along with its subsidiaries, offers human resources platform solutions in Japan and has a market capitalization of ¥319.18 billion.

Operations: The company's revenue is primarily derived from HR Tech, which contributes ¥63.84 billion, and Incubation, which adds ¥2.26 billion.

Insider Ownership: 39.2%

Revenue Growth Forecast: 10.8% p.a.

Visional's growth prospects are supported by earnings forecasted to increase 12.5% annually, surpassing the JP market's average growth. The company's revenue is also expected to grow at 10.8% per year, faster than the market rate of 4.2%. Trading significantly below its estimated fair value enhances its investment appeal, while no substantial insider trading activity in recent months indicates stability. Recent guidance projects JPY 76.4 billion in net sales for fiscal year ending July 2025.

TSE:4194 Earnings and Revenue Growth as at Dec 2024
TSE:4194 Earnings and Revenue Growth as at Dec 2024

Key Takeaways

Seeking Other Investments?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com